Lupin Limited

Lupin Limited

LUPIN.NSApproved

Lupin Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with over four decades of experience in developing, manufacturing, and marketing generic and branded pharmaceutical products. The company has built a strong portfolio of complex generics, particularly in respiratory and cardiovascular therapies, with key products including generic versions of Spiriva, ProAir, and various oral contraceptives. Lupin operates a global supply chain with manufacturing facilities in India, the US, Mexico, and other countries, serving patients in over 100 countries worldwide.

Market Cap
$11.3B
Employees
15,000-20,000
Focus
Biotech

LUPIN.NS · Stock Price

USD 2319.00+1618.20 (+230.91%)

Historical price data

AI Company Overview

Lupin Limited is a multinational pharmaceutical company headquartered in Mumbai, India, with over four decades of experience in developing, manufacturing, and marketing generic and branded pharmaceutical products. The company has built a strong portfolio of complex generics, particularly in respiratory and cardiovascular therapies, with key products including generic versions of Spiriva, ProAir, and various oral contraceptives. Lupin operates a global supply chain with manufacturing facilities in India, the US, Mexico, and other countries, serving patients in over 100 countries worldwide.

Technology Platform

Lupin specializes in complex generic drug development with advanced capabilities in respiratory drug delivery systems, biosimilars, and specialized pharmaceutical formulations including inhalation products and controlled-release systems.

Pipeline Snapshot

1

1 drug in pipeline, 1 in Phase 3

DrugIndicationStage
Escitalopram + Bupropion XLBipolar I DisorderPhase 3

Funding History

1
IPOUndisclosedUndisclosedJun 15, 2000

FDA Approved Drugs

238
BRIVARACETAMANDAFeb 23, 2026
ARMLUPEGBLANov 28, 2025
RIVAROXABANANDASep 25, 2025

Opportunities

Lupin has significant growth opportunities in complex generics, biosimilars, and expanding its respiratory portfolio with high-barrier products.
The company is well-positioned to benefit from the growing generic drug market in the US and emerging markets expansion.

Risk Factors

Key risks include regulatory compliance challenges, intense price competition in generic markets, and potential patent litigation.
The company also faces foreign exchange exposure and dependency on US market approvals for growth.

Competitive Landscape

Lupin competes with major generics companies like Teva, Viatris, and Sun Pharma, differentiating through its respiratory expertise and complex generics capabilities. The company's focus on high-barrier products and cost-effective Indian manufacturing provides competitive advantages in price-sensitive markets.

Publications
20
Patents
20
Pipeline
1
FDA Approvals
238

Company Info

TypeTherapeutics
Founded1968
Employees15,000-20,000
LocationMumbai, India
StageApproved
RevenueRevenue Generating

Trading

TickerLUPIN.NS
ExchangeNSE

Contact

Therapeutic Areas

RespiratoryCardiovascularCNSWomen's HealthDiabetesGastroenterology

Partners

Various global pharmaceutical distributorsContract manufacturing partners
SIMILAR COMPANIES
Mankind Pharma
Mankind Pharma
Pre-clinical · New Delhi
Sun Pharmaceutical
Sun Pharmaceutical
Pre-clinical ·
Aurobindo Pharma
Aurobindo Pharma
Pre-clinical · Hyderabad
Dr. Reddy's Laboratories
Dr. Reddy's Laboratories
Pre-clinical · Princeton
Abbott India
Abbott India
Pre-clinical · Mumbai
Is this your company?

Claim your profile to update information, add pipeline data, and connect with investors.

Claim profile